Evidence map›Paper›PMID 30208163›Full record

ReviewClinics (Sao Paulo, Brazil)2018

Revisiting the roles of VHR/DUSP3 phosphatase in human diseases.

Lilian Cristina Russo, Jéssica Oliveira Farias, Pault Yeison Minaya Ferruzo, Lucas Falcão Monteiro, Fábio Luís Forti

Open access · goldAbstract readReview
In one paragraph

Review in Clinics (Sao Paulo, Brazil), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. A Review of DUSP26: Structure, Regulation and Relevance in Human Disease.International journal of molecular sciences · 2021
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Lilian Cristina RussoDepartamento de Bioquímica, Instituto de Quimica, Universidade de Sao Paulo, Sao Paulo, SP, BR.
Jéssica Oliveira FariasDepartamento de Bioquímica, Instituto de Quimica, Universidade de Sao Paulo, Sao Paulo, SP, BR.
Pault Yeison Minaya FerruzoDepartamento de Bioquímica, Instituto de Quimica, Universidade de Sao Paulo, Sao Paulo, SP, BR.
Lucas Falcão MonteiroDepartamento de Bioquímica, Instituto de Quimica, Universidade de Sao Paulo, Sao Paulo, SP, BR.
Fábio Luís FortiDepartamento de Bioquímica, Instituto de Quimica, Universidade de Sao Paulo, Sao Paulo, SP, BR.
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein tyrosine phosphatases have long been considered key regulators of biological processes and are therefore implicated in the origins of various human diseases. Heterozygosity, mutations, deletions, and the complete loss of some of these enzymes have been reported to cause neurodegenerative diseases, autoimmune syndromes, genetic disorders, metabolic diseases, cancers, and many other physiological imbalances. Vaccinia H1-related phosphatase, also known as dual-specificity phosphatase 3, is a protein tyrosine phosphatase enzyme that regulates the phosphorylation of the mitogen-activated protein kinase signaling pathway, a central mediator of a diversity of biological responses. It has been suggested that vaccinia H1-related phosphatase can act as a tumor suppressor or tumor-promoting phosphatase in different cancers. Furthermore, emerging evidence suggests that this enzyme has many other biological functions, such as roles in immune responses, thrombosis, hemostasis, angiogenesis, and genomic stability, and this broad spectrum of vaccinia H1-related phosphatase activity is likely the result of its diversity of substrates. Hence, fully identifying and characterizing these substrate-phosphatase interactions will facilitate the identification of pharmacological inhibitors of vaccinia H1-related phosphatase that can be evaluated in clinical trials. In this review, we describe the biological processes mediated by vaccinia H1-related phosphatase, especially those related to genomic stability. We also focus on validated substrates and signaling circuitry with clinical relevance in human diseases, particularly oncogenesis.

Indexed as

Dual Specificity Phosphatase 3HumansMitogen-Activated Protein KinasesNeoplasmsSignal TransductionSurvival AnalysisDual Specificity Phosphatase 3Mitogen-Activated Protein Kinases

Identifiers

PMID30208163
PMCPMC6113852
OpenAlexW2897986932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.